BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $62.26 -1.75%
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.54, $0.31 better than the analyst estimate of $0.23. Revenue for the quarter came in at $595.3 million versus the consensus estimate of $595.22 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.02. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 million, versus the consensus of $2.46 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
- KB Home (KBH) Tops Q3 EPS by 16c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
